Rho-kinase inhibition: a novel therapeutic target for the treatment of cardiovascular diseases.

The Rho/rho-kinase (ROCK) pathway has an important role in the pathogenesis of several cardiovascular diseases. The activation of ROCK is involved in the regulation of vascular tone, endothelial dysfunction, inflammation and remodeling. The inhibition of ROCK has a beneficial effect in a variety of cardiovascular disorders. Evidence from animal models and from clinical use of ROCK inhibitors, such as Y-27632, fasudil and statins (i.e. pleiotropic effects), supports the hypothesis that ROCK is a potential therapeutic target. This review provides a current understanding of the role of ROCK pathway in the regulation of vascular function and the use of ROCK inhibitors in the treatment of cardiovascular disorders.

[1]  H. Shimokawa,et al.  Effects of Rho-kinase inhibitor on vasopressin-induced chronic myocardial damage in rats. , 2002, Life sciences.

[2]  A. Takeshita,et al.  Suppression of Coronary Artery Spasm by the Rho-Kinase Inhibitor Fasudil in Patients With Vasospastic Angina , 2002, Circulation.

[3]  H. Shimokawa,et al.  Antianginal effects of hydroxyfasudil, a Rho‐kinase inhibitor, in a canine model of effort angina , 2001, British journal of pharmacology.

[4]  M. Moskowitz,et al.  Inhibition of Rho Kinase (ROCK) Leads to Increased Cerebral Blood Flow and Stroke Protection , 2005, Stroke.

[5]  S. Hosoda,et al.  Anti-anginal Effect of Fasudil, a Rho-Kinase Inhibitor, in Patients With Stable Effort Angina: A Multicenter Study , 2002, Journal of cardiovascular pharmacology.

[6]  C. Bouchard,et al.  A Major Haplotype Block at the Rho-Associated Kinase 2 Locus Is Associated with a Lower Risk of Hypertension in a Recessive Manner: The HYPGENE Study , 2008, Hypertension Research.

[7]  A. Takeshita,et al.  Long-term inhibition of Rho-kinase induces a regression of arteriosclerotic coronary lesions in a porcine model in vivo. , 2001, Cardiovascular research.

[8]  K. Kaibuchi,et al.  Rho-Rho-kinase pathway in smooth muscle contraction and cytoskeletal reorganization of non-muscle cells. , 2001, Trends in pharmacological sciences.

[9]  R. Schwartz,et al.  Rho kinases play an obligatory role in vertebrate embryonic organogenesis. , 2001, Development.

[10]  T. Saruta,et al.  Vessel- and Vasoconstrictor-Dependent Role of Rho/Rho-Kinase in Renal Microvascular Tone , 2003, Journal of Vascular Research.

[11]  H. Hidaka,et al.  Vasodilator actions of HA1077 in vitro and in vivo putatively mediated by the inhibition of protein kinase , 1989, British journal of pharmacology.

[12]  S. Narumiya,et al.  Citron, a Rho target that affects contractility during cytokinesis , 2000, Microscopy research and technique.

[13]  H. Shimokawa,et al.  Rho-Kinase Mediates Hypoxia-Induced Downregulation of Endothelial Nitric Oxide Synthase , 2002, Circulation.

[14]  H. Shimokawa,et al.  Antiischemic properties of fasudil in experimental models of vasospastic angina. , 2001, Japanese journal of pharmacology.

[15]  Melissa L. Williams,et al.  Direct Rho-associated kinase inhibiton induces cofilin dephosphorylation and neurite outgrowth in PC-12 cells , 2006, Cellular & Molecular Biology Letters.

[16]  J. Liao,et al.  Deficiency of ROCK1 in bone marrow‐derived cells protects against atherosclerosis in LDLR−/− mice , 2008, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[17]  A. Takeshita,et al.  Long-Term Inhibition of Rho-Kinase Suppresses Neointimal Formation After Stent Implantation in Porcine Coronary Arteries: Involvement of Multiple Mechanisms , 2004 .

[18]  John G. Collard,et al.  Activation of RhoA by Thrombin in Endothelial Hyperpermeability: Role of Rho Kinase and Protein Tyrosine Kinases , 2000, Circulation research.

[19]  U. Laufs,et al.  Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. , 1998, Circulation.

[20]  Julie H. Campbell,et al.  Rho and vascular disease. , 2005, Atherosclerosis.

[21]  T. Lüscher,et al.  Statin Prevents Tissue Factor Expression in Human Endothelial Cells: Role of Rho/Rho-Kinase and Akt Pathways , 2002, Circulation.

[22]  F. Luscinskas,et al.  ROCK1 mediates leukocyte recruitment and neointima formation following vascular injury. , 2008, The Journal of clinical investigation.

[23]  A. Takeshita,et al.  Possible Involvement of Rho-Kinase in the Pathogenesis of Hypertension in Humans , 2001, Hypertension.

[24]  K. Kaibuchi,et al.  Long-Term Inhibition of Rho-kinase Ameliorates Hypoxia-Induced Pulmonary Hypertension in Mice , 2006, Journal of cardiovascular pharmacology.

[25]  A. Gilman,et al.  p115 RhoGEF, a GTPase activating protein for Gα12 and Gα13 , 1998 .

[26]  Shuh Narumiya,et al.  An essential part for Rho–associated kinase in the transcellular invasion of tumor cells , 1999, Nature Medicine.

[27]  J. Liao,et al.  Evidence for Statin Pleiotropy in Humans: Differential Effects of Statins and Ezetimibe on Rho-Associated Coiled-Coil Containing Protein Kinase Activity, Endothelial Function, and Inflammation , 2009, Circulation.

[28]  A. Takeshita,et al.  Acute vasodilator effects of a Rho-kinase inhibitor, fasudil, in patients with severe pulmonary hypertension , 2005, Heart.

[29]  R. Pluta.  Delayed cerebral vasospasm and nitric oxide: review, new hypothesis, and proposed treatment. , 2005, Pharmacology & therapeutics.

[30]  P. Ganz,et al.  Statins inhibit Rho kinase activity in patients with atherosclerosis. , 2009, Atherosclerosis.

[31]  B. Yan,et al.  Current status of rho-associated kinases (ROCKs) in coronary atherosclerosis and vasospasm. , 2009, Cardiovascular & Hematological Agents in Medicinal Chemistry.

[32]  S. Bolz,et al.  Nitric Oxide‐Induced Decrease in Calcium Sensitivity of Resistance Arteries Is Attributable to Activation of the Myosin Light Chain Phosphatase and Antagonized by the RhoA/Rho Kinase Pathway , 2003, Circulation.

[33]  H. Meurs,et al.  The inhaled Rho kinase inhibitor Y-27632 protects against allergen-induced acute bronchoconstriction, airway hyperresponsiveness, and inflammation. , 2008, American journal of physiology. Lung cellular and molecular physiology.

[34]  P. Stern,et al.  Rho and Rho Kinase Are Involved in Parathyroid Hormone‐Stimulated Protein Kinase C α Translocation and IL‐6 Promoter Activity in Osteoblastic Cells , 2004, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[35]  J. Passauer,et al.  Role of rho-kinase in the regulation of vascular tone in hypertensive renal transplant recipients. , 2009, Atherosclerosis.

[36]  B. Alicke,et al.  The Rho kinase inhibitor fasudil inhibits tumor progression in human and rat tumor models , 2006, Molecular Cancer Therapeutics.

[37]  H. Frierson,et al.  PRK1 distribution in normal tissues and carcinomas: overexpression and activation in ovarian serous carcinoma. , 2009, Human pathology.

[38]  P. Libby.  Inflammation in atherosclerosis , 2002, Nature.

[39]  A. Takeshita,et al.  Rho-kinase-mediated pathway induces enhanced myosin light chain phosphorylations in a swine model of coronary artery spasm. , 1999, Cardiovascular research.

[40]  P. Pacaud,et al.  Rho kinases in cardiovascular physiology and pathophysiology. , 2006, Circulation research.

[41]  H. Saya,et al.  Localization of the gene coding for ROCK II/Rho kinase on human chromosome 2p24. , 1999, Genomics.

[42]  Young-Bum Kim,et al.  Role of Rho-kinase in regulation of insulin action and glucose homeostasis. , 2005, Cell metabolism.

[43]  F. Kajiya,et al.  Beneficial effect of hydroxyfasudil, a specific Rho-kinase inhibitor, on ischemia/reperfusion injury in canine coronary microcirculation in vivo. , 2005, Journal of the American College of Cardiology.

[44]  K. Takeda,et al.  Rho-Kinase Mediates Angiotensin II-Induced Monocyte Chemoattractant Protein-1 Expression in Rat Vascular Smooth Muscle Cells , 2001, Hypertension.

[45]  D. Behm,et al.  Novel Rho Kinase Inhibitors with Anti-inflammatory and Vasodilatory Activities , 2007, Journal of Pharmacology and Experimental Therapeutics.

[46]  H. Shimokawa,et al.  Usefulness of Fasudil, a Rho-kinase Inhibitor, to Treat Intractable Severe Coronary Spasm after Coronary Artery Bypass Surgery , 2004, Journal of cardiovascular pharmacology.

[47]  K. Takeda,et al.  Critical Role of Rho-Kinase and MEK/ERK Pathways for Angiotensin II-Induced Plasminogen Activator Inhibitor Type-1 Gene Expression , 2001, Arteriosclerosis, thrombosis, and vascular biology.

[48]  K. Kaibuchi,et al.  Rho-Kinase Is Involved in Macrophage-Mediated Formation of Coronary Vascular Lesions in Pigs In Vivo , 2000, Arteriosclerosis, thrombosis, and vascular biology.

[49]  H. Hidaka,et al.  Development of specific Rho-kinase inhibitors and their clinical application. , 2005, Biochimica et biophysica acta.

[50]  K. Kaibuchi,et al.  Rho GTPase/Rho Kinase Negatively Regulates Endothelial Nitric Oxide Synthase Phosphorylation through the Inhibition of Protein Kinase B/Akt in Human Endothelial Cells , 2002, Molecular and Cellular Biology.

[51]  H. Hidaka,et al.  The novel and specific Rho-kinase inhibitor (S)-(+)-2-methyl-1-[(4-methyl-5-isoquinoline)sulfonyl]-homopiperazine as a probing molecule for Rho-kinase-involved pathway. , 2002, Pharmacology & therapeutics.

[52]  P. Burbelo,et al.  The RhoA-binding protein, Rhophilin-2, Regulates Actin Cytoskeleton Organization* , 2002, The Journal of Biological Chemistry.

[53]  A. Takeshita,et al.  Long-Term Inhibition of Rho-Kinase Suppresses Left Ventricular Remodeling After Myocardial Infarction in Mice , 2004, Circulation.

[54]  A. Tedgui,et al.  Rho-Associated Protein Kinase Contributes to Early Atherosclerotic Lesion Formation in Mice , 2003, Circulation research.

[55]  V. V. van Hinsbergh,et al.  Role of RhoA and Rho kinase in lysophosphatidic acid-induced endothelial barrier dysfunction. , 2000, Arteriosclerosis, thrombosis, and vascular biology.

[56]  K. Nakao,et al.  ROCK‐I and ROCK‐II, two isoforms of Rho‐associated coiled‐coil forming protein serine/threonine kinase in mice , 1996, FEBS letters.

[57]  H. Hidaka,et al.  H-series protein kinase inhibitors and potential clinical applications. , 1999, Pharmacology & therapeutics.

[58]  Hiroaki Shimokawa,et al.  Statins prevent pulsatile stretch-induced proliferation of human saphenous vein smooth muscle cells via inhibition of Rho/Rho-kinase pathway. , 2005, Cardiovascular research.

[59]  B. Chaitman,et al.  Efficacy and safety of fasudil in patients with stable angina: a double-blind, placebo-controlled, phase 2 trial. , 2005, Journal of the American College of Cardiology.

[60]  T. Kobayashi,et al.  Pharmacological profile of hydroxy fasudil as a selective rho kinase inhibitor on ischemic brain damage. , 2001, Life sciences.

[61]  Y. R. Jarajapu,et al.  Relative contribution of Rho kinase and protein kinase C to myogenic tone in rat cerebral arteries in hypertension. , 2005, American journal of physiology. Heart and circulatory physiology.

[62]  D. Linseman,et al.  Diverse roles of Rho family GTPases in neuronal development, survival, and death. , 2008, Frontiers in bioscience : a journal and virtual library.

[63]  A. Takeshita,et al.  [Inhibition of Rho-kinase by fasudil preventing anginal attacks associated with spastic angina: a case report]. , 2004, Journal of cardiology.

[64]  R. Treisman,et al.  Transformation mediated by RhoA requires activity of ROCK kinases , 1999, Current Biology.

[65]  K. Kugiyama,et al.  Coronary spasm: clinical features and pathogenesis. , 1997, Internal medicine.

[66]  H. Kishida,et al.  Administration of the Rho-kinase inhibitor, fasudil, following nitroglycerin additionally dilates the site of coronary spasm in patients with vasospastic angina , 2008, Coronary artery disease.

[67]  R. Perona,et al.  Multiple Signalling Pathways Lead to the Activation of the Nuclear Factor κB by the Rho Family of GTPases* , 1998, The Journal of Biological Chemistry.

[68]  D. Lesieur,et al.  Rho-kinase Inhibitors: Pharmacomodulations on the Lead Compound Y-32885 , 2002, Journal of enzyme inhibition and medicinal chemistry.

[69]  T. Yamakawa,et al.  Involvement of Rho-kinase in angiotensin II-induced hypertrophy of rat vascular smooth muscle cells. , 2000, Hypertension.

[70]  A. Takeshita,et al.  Divergent effects of estrogen and nicotine on Rho-kinase expression in human coronary vascular smooth muscle cells. , 2004, Biochemical and biophysical research communications.

[71]  A. Takeshita,et al.  Enhanced myosin light chain phosphorylations as a central mechanism for coronary artery spasm in a swine model with interleukin-1beta. , 1997, Circulation.

[72]  Shuh Narumiya,et al.  Calcium sensitization of smooth muscle mediated by a Rho-associated protein kinase in hypertension , 1997, Nature.

[73]  T. Iwama,et al.  Fasudil, a Rho kinase (ROCK) inhibitor, protects against ischemic neuronal damage in vitro and in vivo by acting directly on neurons , 2007, Brain Research.

[74]  C. Kataoka,et al.  Antiinflammatory and Antiarteriosclerotic Actions of HMG-CoA Reductase Inhibitors in a Rat Model of Chronic Inhibition of Nitric Oxide Synthesis , 2001, Circulation research.

[75]  C. Heeschen,et al.  Differential effects of short-term lipid lowering with ezetimibe and statins on endothelial function in patients with CAD: clinical evidence for 'pleiotropic' functions of statin therapy. , 2006, European heart journal.

[76]  D. Epstein,et al.  Expression of dominant negative Rho-binding domain of Rho-kinase in organ cultured human eye anterior segments increases aqueous humor outflow. , 2005, Molecular vision.

[77]  K. Kaibuchi,et al.  Involvement of Rho-kinase-mediated phosphorylation of myosin light chain in enhancement of cerebral vasospasm. , 2000, Circulation research.

[78]  P. Cohen,et al.  Specificity and mechanism of action of some commonly used protein kinase inhibitors , 2000 .

[79]  M. Humbert,et al.  RhoA and Rho kinase activation in human pulmonary hypertension: role of 5-HT signaling. , 2009, American journal of respiratory and critical care medicine.

[80]  A. Takeshita,et al.  Involvement of Rho-Kinase in Agonists-Induced Contractions of Arteriosclerotic Human Arteries , 2002, Arteriosclerosis, thrombosis, and vascular biology.

[81]  A. Takeshita,et al.  Inflammatory stimuli upregulate Rho-kinase in human coronary vascular smooth muscle cells. , 2004, Journal of molecular and cellular cardiology.

[82]  V. Niggli.  Rho‐kinase in human neutrophils: a role in signalling for myosin light chain phosphorylation and cell migration , 1999, FEBS letters.

[83]  A. Takeshita,et al.  Long-Term Treatment With a Specific Rho-Kinase Inhibitor Suppresses Cardiac Allograft Vasculopathy in Mice , 2004, Circulation research.

[84]  Y. Hirooka,et al.  Therapeutic Potential of Rho-Kinase Inhibitors in Cardiovascular Diseases , 2005, American journal of cardiovascular drugs : drugs, devices, and other interventions.

[85]  S. Rivkees,et al.  Rho‐associated kinases play an essential role in cardiac morphogenesis and cardiomyocyte proliferation , 2003, Developmental dynamics : an official publication of the American Association of Anatomists.

[86]  A. Takeshita,et al.  Rho-Kinase Is an Important Therapeutic Target in Cardiovascular Medicine , 2005 .

[87]  T. Kobayashi,et al.  Inhibition of neutrophil migration by a protein kinase inhibitor for the treatment of ischemic brain infarction. , 1999, Japanese journal of pharmacology.

[88]  Hiroto Yamaguchi,et al.  Molecular mechanism for the regulation of rho-kinase by dimerization and its inhibition by fasudil. , 2006, Structure.

[89]  K. Kaibuchi,et al.  Long-Term Treatment With a Rho-Kinase Inhibitor Improves Monocrotaline-Induced Fatal Pulmonary Hypertension in Rats , 2004, Circulation research.

[90]  Michael D. Schneider,et al.  Targeted deletion of ROCK1 protects the heart against pressure overload by inhibiting reactive fibrosis , 2006, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[91]  A. Somlyo,et al.  Ca2+ sensitivity of smooth muscle and nonmuscle myosin II: modulated by G proteins, kinases, and myosin phosphatase. , 2003, Physiological reviews.

[92]  M. Essig,et al.  3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors increase fibrinolytic activity in rat aortic endothelial cells. Role of geranylgeranylation and Rho proteins. , 1998, Circulation research.

[93]  S. Hirai,et al.  Effects of fasudil in acute ischemic stroke: Results of a prospective placebo-controlled double-blind trial , 2005, Journal of the Neurological Sciences.

[94]  L. Fink,et al.  Comparative gene expression profiling in three primary human cell lines after treatment with a novel inhibitor of Rho kinase or atorvastatin , 2008, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[95]  J. Liao,et al.  Inhibition of Rho-Kinase Leads to Rapid Activation of Phosphatidylinositol 3-Kinase/Protein Kinase Akt and Cardiovascular Protection , 2004, Arteriosclerosis, thrombosis, and vascular biology.

[96]  R. Myers,et al.  TNF-&agr; and TNF-&agr; Receptor Type 1 Upregulation in Glia and Neurons After Peripheral Nerve Injury: Studies in Murine DRG and Spinal Cord , 2004 .

[97]  P. Lograsso,et al.  Structure-activity relationships, and drug metabolism and pharmacokinetic properties for indazole piperazine and indazole piperidine inhibitors of ROCK-II. , 2007, Bioorganic & medicinal chemistry letters.

[98]  H. Shimokawa.  Rho-kinase as a Novel Therapeutic Target in Treatment of Cardiovascular Diseases , 2002, Journal of cardiovascular pharmacology.

[99]  S. Takai,et al.  Involvement of Rho-kinase in tumor necrosis factor-α-induced interleukin-6 release from C6 glioma cells , 2009, Neurochemistry International.

[100]  N. Voelkel,et al.  Rho Kinase-Mediated Vasoconstriction Is Important in Severe Occlusive Pulmonary Arterial Hypertension in Rats , 2007, Circulation research.

[101]  J. Wilcox,et al.  Identification of a potential role for the adventitia in vascular lesion formation after balloon overstretch injury of porcine coronary arteries. , 1996, Circulation.

[102]  J. Wilcox,et al.  Potential role of the adventitia in arteritis and atherosclerosis. , 1996, International journal of cardiology.

[103]  A. Takeshita,et al.  Long-Term Inhibition of Rho-Kinase Suppresses Angiotensin II–Induced Cardiovascular Hypertrophy in Rats In Vivo: Effect on Endothelial NAD(P)H Oxidase System , 2003, Circulation research.

[104]  W. Bao,et al.  Inhibition of Rho-kinase protects the heart against ischemia/reperfusion injury. , 2004, Cardiovascular research.

[105]  Timothy J Mitchison,et al.  Screening for cell migration inhibitors via automated microscopy reveals a Rho-kinase inhibitor. , 2005, Chemistry & biology.

[106]  M. Aepfelbacher,et al.  Mildly Oxidized Low Density Lipoprotein Induces Contraction of Human Endothelial Cells through Activation of Rho/Rho Kinase and Inhibition of Myosin Light Chain Phosphatase* , 1999, The Journal of Biological Chemistry.

[107]  J. Rajfer,et al.  Therapy of erectile dysfunction , 2004, Endocrine.

[108]  N. Schneiderhan-Marra,et al.  Monitoring the Cellular Effects of HMG-CoA Reductase Inhibitors In Vitro and Ex Vivo , 2004, Arteriosclerosis, thrombosis, and vascular biology.

[109]  K. Sunagawa,et al.  Rho-Kinase Inhibitor Improves Increased Vascular Resistance and Impaired Vasodilation of the Forearm in Patients With Heart Failure , 2005, Circulation.

[110]  M. R. De Bittner,et al.  Potential Use of HMG-CoA Reductase Inhibitors for Osteoporosis , 2002, The Annals of pharmacotherapy.

[111]  S. Narumiya,et al.  Pharmacological properties of Y-27632, a specific inhibitor of rho-associated kinases. , 2000, Molecular pharmacology.

[112]  H. Kishida,et al.  Vasodilatory effect of subsequent administration of fasudil, a rho-kinase inhibitor, surpasses that of nitroglycerin at the concentric coronary stenosis in patients with stable angina pectoris. , 2006, Circulation journal : official journal of the Japanese Circulation Society.

[113]  M. Yano,et al.  Enhancement of Rho/Rho-kinase system in regulation of vascular smooth muscle contraction in tachycardia-induced heart failure. , 2001, Cardiovascular research.

[114]  G. Baxter,et al.  Rho kinase activation plays a major role as a mediator of irreversible injury in reperfused myocardium. , 2007, American journal of physiology. Heart and circulatory physiology.

[115]  I. Ikegaki,et al.  Hemorheological abnormalities in experimental cerebral ischemia and effects of protein kinase inhibitor on blood fluidity. , 2000, Life sciences.

[116]  A. Takeshita,et al.  Inhibition of myosin phosphatase by upregulated rho-kinase plays a key role for coronary artery spasm in a porcine model with interleukin-1beta. , 2000, Circulation.

[117]  K. Fujisawa,et al.  The small GTP‐binding protein Rho binds to and activates a 160 kDa Ser/Thr protein kinase homologous to myotonic dystrophy kinase. , 1996, The EMBO journal.

[118]  H. Hidaka,et al.  The Effect of the H-1152P, a Potent Rho-Associated Coiled Coil-Formed Protein Kinase Inhibitor, in Rabbit Normal and Ocular Hypertensive Eyes , 2009, Current eye research.